Leuven, Belgium, Tuesday, November 3th, 2020 – ArtiQ, a Belgian start-up with the mission to empower medical professionals with artificial intelligence to more timely and accurately diagnose, treat, and follow-up patients with lung diseases, has been awarded a € 450 000 grant by Flanders Innovation and Entrepreneurship (VLAIO).

Marko Topalovic, CEO and co-founder of ArtiQ: “With the support of VLAIO, we gained an important partner towards long-term value creation for our customers. The support will help us to position ourselves as a leading software company in the respiratory medicine sector.” He further adds: “We are very grateful to VLAIO for their trust and recognition. We plan to use this support to boost our product portfolio diversification and expansion on the new markets.”

The grant will accelerate the research required to further build the ArtiQ product portfolio. It will allow developing additional functionality for the current product ArtiQ.PFT to offer improved support to physicians diagnosing and treating lung diseases.  Subsequently, it will contribute to the best care for patients with respiratory disease, a patient group significantly impacted in the world today. Further, the VLAIO support will be used to create new products in line with the company’s mission to empower the different players in the respiratory medicine eco-system with AI solutions to more timely and accurately diagnose, treat, and follow-up patients with lung diseases. The first area of focus is developments that will make a substantial impact on respiratory drug development by making clinical trials more efficient and effective.


Flanders Innovation & Entrepreneurship is the contact point for entrepreneurs in Flanders. They encourage and support innovation and entrepreneurship, and contribute to a favorable business climate. By being a one-stop-shop, they build a bridge towards stronger entrepreneurship.

About ArtiQ & ArtiQ.PFT

ArtiQ is a young, dynamic, and innovative spin-off company of the University of Leuven (Belgium). The company was founded in early 2019 by four committed founders with an extensive history in respiratory medicine, medical devices, and artificial intelligence. ArtiQ’s mission is to empower medical professionals with artificial intelligence to accurately and timely diagnose, treat and follow-up patients with lung diseases.

The ArtiQ.PFT software automates the interpretation of pulmonary function tests (PFTs). It reduces the administrative burden to allow pulmonologists to focus on clinical decision making and patient consult. ArtiQ.PFT uses artificial intelligence (AI) to support the detection of disease patterns early on in the diagnostic process and thus holds the potential to reduce redundant testing.

Close Menu